Adverum Biotechnologies Reports Second Quarter 2022 Financial Results
REDWOOD CITY, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the second quarter ended June 30, 2022.
- - Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated throughout 2023
REDWOOD CITY, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced financial results for the second quarter ended June 30, 2022. - In April 2022, the U.S. Food and Drug Administration (FDA) provided Adverum with Type C Meeting feedback.
- Stock-based compensation expense included in research and development expenses was $1.8million for the second quarter of 2022.
- Stock-based compensation expense included in general and administrative expenses was $3.1 million for the second quarter of 2022.